- MitoSense officially joins CAMP as a partner for the development of advanced therapy medicinal products (ATMP)

PLYMOUTH, Mass., July 24, 2023 /PRNewswire/ -- MitoSense and the Center for Advanced Medical Products (CAMP) are pleased to announce that MitoSense has officially joined CAMP as an Advanced Therapy Drug (ATMP) development partner.

MitoSense, Inc. is a leading biotechnology company focused on developing advanced therapies for neurodegenerative diseases using Mitochondria Organelle Transplantation (MOT™) technology. The company's patented MOT™ technology has shown promising results in the treatment of mitochondrial dysfunction and could also be applied to the CARMEV project by improving extracellular vesicles (EVs) from bone marrow MSCs to inhibit ischemia-reperfusion injury after myocardial infarction (MI).

Van Hipp, President of MitoSense, commented, "We are delighted to partner with CAMP, a prestigious organization dedicated to the development of ATMP. This partnership allows us to combine our unique MOT™ technology with CAMP's expertise, accelerating the development of life-changing therapies for patients suffering from neurodegenerative diseases."

CAMP is a leading research center focusing on bioprocess development, GMP production, and logistics for ATMP development and translation. By bringing together a wide range of stakeholders, including university hospitals, research institutes and industry, CAMP is driving innovation and collaboration in ATMP development and ultimately delivering these life-changing therapies to those who need them.

Karl-Henrik Grinnemo, Principal Investigator at Uppsala University Hospital, said: "We are excited to welcome MitoSense as a partner in the CARMEV project. Its cutting-edge MOT™ technology has great potential to revolutionize the treatment of neurodegenerative diseases and prevent heart failure. We look forward to working together to bring these innovative therapies to patients."

MitoSense's commitment to rigorous research and clinical trials to validate the safety and efficacy of its therapies aligns with the goals of the CARMEV project to characterize biologically active VE preparations and confirm the safety of the VE product in in vivo preclinical experiments and in vitro human testing. By collaborating with CAMP and leveraging their expertise in cellular biotherapies, MitoSense can work to generate a well-characterized final VE product under GMP conditions.

MitoSense is contributing in-kind contributions consisting of materials and staff resources up to a level of around SEK 800,000 per year.

For more information about MitoSense and CAMP, please visit https://www.mitosenseinc.com and https://atmpsweden.se/about-atmp-sweden/current-initiatives/about-camp/, respectively.

Logo - https://mma.prnewswire.com/media/1735129...

View original content: https://www.prnewswire.com/news-releases/mitosense-se-une-a-camp-para-desarrollar-productos-medicinales-de-terapia-avanzada-301883715.html